WEBINARS

Free public webinar series presented by leading medicines policy researchers. The webinars aim to make recent, policy-relevant research more accessible to a global public audience and facilitate flows of knowledge between the research and policy & practice communities.

 

Past webinars (recordings and materials available on links)

​

​

Dec 2021 | Joseph Larsen, Venatorx Pharmaceuticals; Former BARDA; Daniel P. Gross, Duke University Fuqua School of Business, and National Bureau of Economic Research

• Biosecurity R&D: lessons from the U.S. from pre-Covid to post-Covid

​

​

Nov 2021 | Donald W. Light, Professor of comparative health policy and psychiatry, School of Osteopathic Medicine, Rowan University, Stratford; Adjunct professor in medical ethics, New York University

• Assessing public contributions to drug development: a novel framework 

​

​​

Oct 2021 | Gabriela Costa Chaves, Independent Researcher; Pauline Londeix, Observatoire de la Transparence dans les Politiques du Médicament (OTMeds)

• Local production of essential medicines in Brazil and Europe: lessons and future directions

​

​

June 2021 | Eduardo Urias, Assistant Professor, Faculty of Science, Athena Institute, VU University Amsterdam; Danielle Navarro, Research Assistant, Global Health Centre

• Effectiveness and limitations of compulsory licenses to promote access to medicines

​

​

April 2021 | Manica Balasegaram, Executive Director, GARDP - Global Antibiotic Research and Development Partnership; Michelle Childs, Director of Policy Advocacy, DNDi - Drugs for Neglected Diseases initiative

• What lessons from Covid-19 for advancing antibiotic R&D?

​

March 2021 | Marcela Vieira, Researcher and Project Coordinator of the Knowledge Network for Innovation and Access to Medicines, Global Health Centre, IHEID

• Non-commercial pharmaceutical R&D: what do PDPs suggest about costs and efficiency?

​

​

February 2021 | Monirul Azam, Associate professor in Law, Södertörn University and Adjunct faculty in Intellectual Property Law, Stockholm University; Sangeeta Shashikant, Development and Intellectual Property, Third World Network

• The implementation of the TRIPS Agreement by Least Developed Countries: preserving policy space for innovation and access to medicines​

November 2020 | Ayesha Sitlani, Associate Vice President - Antibody Strategy, International AIDS Vaccine Initiative (IAVI)

• Monoclonal antibodies (mAbs) for the treatment and prevention of diseases: why and how to expand global access

​

October 2020 | Julia Barnes-Weise, The Global Health Innovation Alliance Accelerator (GHIAA); Viviana Galli, European Alliance for Responsible R&D and Affordable Medicines

• Building access into pharmaceutical R&D agreements: ideas and possibilities from real-world contracts​​

September 2020 | David Levine, Elon University School of Law

• Trade secrets: implications for pharmaceutical innovation and access

​

​

June 2020 | Julia Paranhos, Federal University of Rio de Janeiro; Ellen 't Hoen, Medicines Law & Policy

• Extending monopolies: evidence from Brazil and Europe on the impact on innovation and access to medicines

​

April 2020 | Yousuf Vawda, University of KwaZulu-Natal; Lynette Mabote, Southern African Programme on Access to Medicines and Diagnostics (SAPAM)

• TRIPS Flexibilities In Africa: Are Countries Equipped to Protect Public Health?

​

​

March 2020 | Dzintars Gotham, Independent researcher; Lindsay McKenna, Treatment Action Group (TAG)

• How much does it cost to develop a new medicine? Public versus private investments in the TB drug bedaquiline

​

​

February 2020 | Suerie Moon, Global Health Centre, Graduate Institute of Geneva; Tania Cernuschi, World Health Organization

• Fair pricing of medicines: what lessons from growing transparency in vaccines prices?

​

December 2019 | Elena Lungu, Manager of Policy Development, Patented Medicine Prices Review Board (PMPRB), Canada

• Regulating drug prices: national and global implications of Canada’s recent reforms

​

November 2019 | Slavek Roller, Faculty of Economics and Business, Goethe University Frankfurt; Nadya Wells, Global Health Centre, Graduate Institute of Geneva

• Public Funding of Biomedical R&D: What Role for Public Investment Funds and Financial Markets?

​

October 2019 | Peter Yu, Center for Law and Intellectual Property at Texas A&M University; Yuanqiong Hu, Access Campaign of Médecins Sans Frontières (MSF)

• China’s changing role in the global pharmaceutical system: implications for national and global public health

​

September 2019 | Reed Beall, University of Calgary; Mayra Vasquez,  National College of Pharmaceutical Chemists of Colombia; Miguel Cortes,  UNOPS (United Nations Office for Project Services)

• Is Data Exclusivity Justified? Evidence on the Impacts on Innovation and Access to Medicines​

​

June 2019 | Marg Ewen and Molly Lepeska, Health Action International

• Global access to affordable insulin: understanding the barriers

​

​

April 2019 | Ekaterina Cleary, Bentley University

• Public funding of drug development: contributions of the US NIH

​

​

March 2019 | Kiu Tay-Teo, World Health Organization

• R&D costs of cancer medicines: how does it compare with sales income?

​

​

February 2019 | Carolina Gomez, INVIMA - Instituto Nacional de Vigilancia de Medicamentos y Alimentos (Colombia’s National Institute of Food and Drug Monitoring)

• Regulation to accelerate access to biosimilars: Colombia's pioneering approach

​

​

January 2019 | Fred Abbott, Florida State University College of Law

• Using competition law to address high medicines prices

​

​

December 2018 | Sabine Vogler, Austrian Public Health Institute (GÖG)

• Addressing high drug prices - what can be learned from European policies?

​

​

November 2018 | Gavin Yamey, Duke University

• New technologies for neglected diseases: what is likely to come out of the pipeline, what is missing, and what will it cost?

​

​

October 2018 | Achal Prabhala, accessibsa: Innovation & Access to Medicines in India, Brazil & South Africa

• A New World Patent Order: An analysis of granted and rejected biomedical patents in India - with implications for Brazil, South Africa & beyond

​

​